NCT00092625CompletedPhase 3
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Organon and Co
- Enrollment
- 442
- Primary Endpoint
- Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment.
Study Overview
Brief Summary
The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
Detailed Description
The duration of treatment is 10 weeks.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with elevated cholesterol and coronary heart disease
Exclusion Criteria
- •Patients who have cholesterol levels within normal ranges as identified by the study
Outcomes
Primary Outcomes
Percentage of patients reaching their target LDL-C goal of </= 2.60 mmol/L, after 6 weeks of treatment.
Secondary Outcomes
- Safety and tolerability.
Investigators
Similar Trials
Completed
Phase 3
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)Coronary DiseaseHypercholesterolemiaNCT00092612Organon and Co372
Completed
Phase 3
An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)Coronary DiseaseHypercholesterolemiaNCT00092638Organon and Co450
Terminated
Phase 3
Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With HypercholesterolemiaHypercholesterolemiaNCT00532558Takeda657
Completed
Phase 3
Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)HypercholesterolemiaNCT00092586Organon and Co2,904
Completed
Phase 3
A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)Type 2 Diabetes MellitusHypercholesterolemiaNCT00110435Organon and Co1,229